Kilitch Drugs (India) Ltd.

₹321.7

5.9 (1.9%)

KILITCH Share Price

Pharmaceuticals & Biotechnology

As on January 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 563 Cr

P/E Ratio19.8

Dividend YieldN/A

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	317.81	Bullish
10-DMA	327.16	Bearish
20-DMA	337.79	Bearish
50-DMA	342.38	Bearish
100-DMA	353.69	Bearish
200-DMA	383.8	Bearish

Historical Performance

1 Year

5.3%

3 Years

117%

5 Years

269.6%

10 Years

672.6%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	1,983	1,544	1,396	1,142	685
Total Expenditure	1,666	1,301	1,219	1,037	632
Other Income	112	45	29	29	27
Operating Profit	429	287	206	134	80
Interest	53	60	51	13	9
Depreciation	31	33	36	25	20
Profit Before Tax	345	194	120	96	51
Consolidated Net Profit	267	146	104	74	37
Adjusted EPS	16	9	7	5	2

Compounded Sales Growth

10 Years:59.8

5 Years:30

3 Years:11.7

TTM:5.1

Compounded Profit Growth

10 Years:100

5 Years:99.6

3 Years:29.4

TTM:12.8

Stock Price CAGR

10 Years:23.1

5 Years:30.1

3 Years:29.5

TTM:2.8

Return on Equity

10 Years:-8.3

5 Years:2.3

3 Years:6.6

last year:16.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	161	161	156	156	155
Total Reserves	1,859	1,599	1,307	1,206	1,113
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	251	-24	-19	-12	-9
Other Current Liabilities	3	3	2	6	14
Short Term Borrowings	217	316	222	204	148
Total Liabilities	3,099	2,375	2,175	2,083	2,019
Capital Work in Progress	473	60	36	32	655
Long Term Loans & Advances	14	7	6	5	4
Currents Investments	495	494	392	472	364
Short Term Loans and Advances	80	80	104	100	49
Total Current Assets	1,739	1,460	1,264	1,141	804
Total Assets	3,099	2,375	2,175	2,083	2,019
Adjusted Book Value	123	107	94	87	82

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 19.8, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 29.6%, indicating sustained price appreciation.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹429 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹1983 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1028436.2

No. of Shares: 3197 (Approx)

Performance:2.8%

P/L: ₹28436.2

NIFTY Performance: 9.4%

1 day Top Gainers